MiNK Therapeutics (NASDAQ:INKT) Downgraded to “Sell” Rating by Wall Street Zen

MiNK Therapeutics (NASDAQ:INKT) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Several other brokerages have also commented on INKT. Weiss Ratings restated a “sell (d-)” rating on shares of MiNK Therapeutics in a research note on Wednesday, October 8th. Zacks Research upgraded shares of MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 20th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $35.00.

MiNK Therapeutics Stock Performance

Shares of NASDAQ INKT opened at $11.59 on Friday. MiNK Therapeutics has a 52-week low of $4.56 and a 52-week high of $76.00. The firm has a market capitalization of $54.36 million, a price-to-earnings ratio of -3.83 and a beta of 0.35. The stock has a 50 day moving average price of $12.75 and a 200 day moving average price of $13.54.

MiNK Therapeutics (NASDAQ:INKT) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.21. Analysts forecast that MiNK Therapeutics will post -2.75 earnings per share for the current year.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.